

QUARTERLY REPORT
FOR THE FIRST QUARTER ENDED 31 MARCH 2015
(The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

	Individual Quarter		Cumulative Quarter	
	Current Year Quarter 31.03.2015	Preceding Year Quarter 31.03.2014	Current Year To Date 31.03.2015	Preceding Year Corresponding Period 31.03.2014
	RM'000	RM'000	RM'000	RM'000
Revenue	4,267	3,854	4,267	3,854
Cost of Sales	(1,596)	(1,686)	(1,596)	(1,686)
Depreciation & Amortisation	(294)	(90)	(294)	(90)
Gross Profit	2,377	2,078	2,377	2,078
Interest Income	614	466	614	466
Other Income	4	(4)	4	(4)
Administrative Expenses	(1,459)	(1,471)	(1,459)	(1,471)
Selling & Distribution Expenses	(1,117)	(700)	(1,117)	(700)
Depreciation & Amortisation	(89)	(139)	(89)	(139)
Profit from Operations	330	230	330	230
Share of Associated Company's Results	(57)	13	(57)	13
Profit Before Taxation	273	243	273	243
Taxation	(63)	(63)	(63)	(63)
Profit Attributable to Ordinary Equity Holders of the Parent	210	180	210	180
Basic profit per share (sen)	0.08	0.07	0.08	0.07
Diluted – profit per share (sen)	0.08	0.07	0.08	0.07
Effective Tax Rate (%)	23.08	25.93	23.08	25.93

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2014.



The Stem Cell Specialist.

**QUARTERLY REPORT
FOR THE FIRST QUARTER ENDED 31 MARCH 2015
(The figures have not been audited)
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

	As at End of Current Quarter 31.03.2015	Audited As at Preceding Financial Year Ended 31.12.2014
	RM'000	RM'000
<u>Non-Current Assets</u>		
Property, Plant and Equipment	10,432	10,046
Investment Properties	3,323	3,663
Intangible Assets	1,931	2,114
Investment in Associated Company	1,538	1,487
	17,224	17,310
<u>Current Assets</u>		
Inventories	642	687
Trade Receivables	4,998	3,967
Other Receivables and Deposits	1,290	1,397
Amount due from Associated Company	1	16
Investment in Money Market	31,573	31,290
Cash and Bank Balances	38,161	38,565
	76,665	75,922
TOTAL ASSETS	93,889	93,232
<u>Equity Attributable to Ordinary Equity Holders of the Parent</u>		
Share Capital	24,750	24,750
Share Premium	3,448	3,448
(Accumulated Losses) / Retained Profit	(3,526)	(3,736)
Exchange Reserve	237	128
	24,909	24,590
<u>Current Liabilities</u>		
Trade Payables	832	568
Advance Payment	64,340	64,297
Advance Billing	1,737	1,506
Other Payables and Accruals	1,275	1,608
Provision	500	500
Amount due to Related Company	192	59
Taxation	104	104
	68,980	68,642
TOTAL LIABILITIES	68,980	68,642
TOTAL EQUITY AND LIABILITIES	93,889	93,232
Net Asset per Share Attributable to Ordinary Equity Holders of the Parent (sen)	10.06	9.94

The Condensed Consolidated Statements of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2014.

QUARTERLY REPORT
FOR THE FIRST QUARTER ENDED 31 MARCH 2015
 (The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Issued and Paid-up Share Capital	Share Premium	Exchange Reserve	Unappropriated Profit	Total
	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 01 January 2015	24,750	3,448	128	(3,736)	24,590
Net Profit for the Period	-	-	109	210	319
Dividend Paid	-	-	-	-	-
Balance as at 31 March 2015	24,750	3,448	237	(3,526)	24,909
Balance as at 01 January 2014	24,750	3,448	(46)	6,066	34,218
Prior Year Adjustment	-	-	80	(447)	(367)
Restated as at 01 January 2014	24,750	3,448	34	5,619	33,851
Net Profit for the Period	-	-	-	180	180
Dividend Paid	-	-	-	-	-
Balance as at 31 March 2014	24,750	3,448	34	5,799	34,031

The Condensed Consolidated Statements of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2014.



The Stem Cell Specialist.

**QUARTERLY REPORT
FOR THE FIRST QUARTER ENDED 31 MARCH 2015
(The figures have not been audited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

CASH FLOWS FROM OPERATING ACTIVITIES

Cash Inflow

Receipts from Customers

Cash Outflow

Payment to Suppliers

Payment for Taxation

Payment for Overheads

Net Cash Flow from Operating Activities

CASH FLOWS FROM INVESTING ACTIVITIES

Cash Inflow

Withdrawal / (Placement) of Deposits

Other Income

Cash Outflow

Purchase of Property, Plant And Equipment

Purchase of Intangible Assets

Net Cash Flow from Investing Activities

CASH FLOWS FROM FINANCING ACTIVITIES

Cash Inflow

Amount Owing by Associated Company

Amount Owing to Related Company

Cash Outflow

Amount Owing by Associated Company

Net Cash Flow from Financing Activities

NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

CASH AND CASH EQUIVALENTS AT END OF PERIOD

Current Year To Date Ended 31.03.2015	Corresponding Year To Date Ended 31.03.2014
RM'000	RM'000
3,511	5,203
1,287	2,321
63	62
2,802	1,572
4,152	3,955
(641)	1,248
-	1,138
335	284
335	1,422
208	79
37	-
245	79
90	1,343
15	-
132	-
147	-
-	3
-	3
147	(3)
(404)	2,588
31,913	40,542
31,509	43,130

**QUARTERLY REPORT
 FOR THE FIRST QUARTER ENDED 31 MARCH 2015
 (The figures have not been audited)
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

	Current Year To Date Ended 31.03.2015 RM'000	Corresponding Year To Date Ended 31.03.2014 RM'000
Cash & Bank Balances	38,161	49,560
Less :Deposit with maturities above three months period	(6,652)	(6,430)
Cash & Cash Equivalents	<u>31,509</u>	<u>43,130</u>

The Condensed Consolidated Statements of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2014.

**QUARTERLY REPORT
FOR THE FIRST QUARTER ENDED 31 MARCH 2015
(The figures have not been audited)**

NOTES TO THE INTERIM FINANCIAL STATEMENTS

PART A – EXPLANATORY NOTES

A 1. Basis of Preparation

The condensed consolidated interim financial statements (Condensed Report) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“MFRS”) 134, Interim Financial Reporting in Malaysia, International Accounting Standard (“IAS”) 34 and Part K, Rule 9.22 (Appendix 9B) of the Listing Requirements of the Bursa Malaysia Securities Berhad (“Securities Exchange”) for the ACE Market.

This Condensed Report does not include all the information required for full annual financial statements and should be read in conjunction with the audited financial statements of StemLife and its subsidiary and associated companies (“the Group”) for the financial year ended 31 December 2014.

The accounting policies used in the preparation of interim financial statements are consistent with those previously adopted in the audited financial statements of the Group for the year ended 31 December 2014.

The explanatory notes attached to this Condensed Report provides an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2014.

A 2. Auditors’ Report on Preceding Annual Financial Statements

The auditors’ report on the financial statements for the financial year ended 31 December 2014 contains a qualified opinion by the external auditors as follows :

- (i) As disclosed in Note 2.5 (b) (iii) to the financial statements, the Group and the Company provide certain benefits under its StemShieldPlus program to its customers as part of the services rendered in relation to the preservation of umbilical cord blood stem cells. The benefits include an undertaking to compensate its customer up to a specified amount for the expenses incurred in the event of a stem cell transplant undertaken for certain diseases. Such benefits meet the definition of an insurance contract pursuant to Malaysian Financial Reporting Standards 4 – Insurance Contracts (“MFRS 4”). However, we noted that the Group and the Company have not complied with the following requirements of MFRS 4:
 - (a) MFRS 4 requires the Group and the Company to assess at each reporting period whether its recognised insurance liabilities are adequate, using current estimates of future cash flows under its insurance contracts. In the event that the carrying amount of its insurance liabilities is inadequate in the light of the estimated future cash flows, the entire deficiency shall be recognised in the statements of comprehensive income.

As disclosed in Note 15 and further explained in Note 2.5 (b) (iii) to the financial statements, the Group and the Company have made a provision for insurance liability of RM500,000 as at 31 December 2014 (2013 and 1.1.2013: RM Nil). However, the basis used in determining the provision amount is not in accordance with the generally accepted method of determining the liabilities in relation to a general insurance contracts, which among others, takes into consideration the age and maturity profile of the insurance contract holders, incidence rates of the diseases by age profile and an appropriate valuation discount rate when estimating the future cash flow under its insurance contracts. Consequently, we were not able to obtain sufficient audit evidence to satisfy ourselves as to the carrying amount of the provision recognised in both the current year and prior year.

- (b) As disclosed in Note 16 (b) to the financial statements, the revenue (insurance premium) associated with the insurance contracts of the Group and the Company for the year ended 31 December 2014 was RM51,600 (2013: RM48,910). However, the amounts recognised were not determined based on the relative fair value of the storage fees and the insurance premium as required by Malaysian Financial Reporting Standards 118: Revenue. Accordingly, we are of the opinion that the above amounts recognised are not appropriate.

The Group and the Company have also not adequately disclosed in the financial statements all other information that identifies and explains the above recognised amounts and the nature and extent of risk from insurance contracts as required under MFRS 4.

- (ii) As disclosed in Note 7 to the financial statements, the Group's investment in an associate, Thai Stemlife Co., Ltd., accounted for using the equity method, is carried at RM1,486,588 (2013: RM1,605,765, 1.1.2013:RM1,607,266) in the statements of financial position as at 31 December 2014 and the Group's share of the associate's net loss of RM212,962 (2013: net profit of RM103,742) is included in the Group's income statements for the year then ended. We were unable to obtain sufficient appropriate audit evidence about the carrying amount of the Group's investment in the associate as at 31 December 2014 and the Group's share of the associate's net loss for the year then ended and its comparatives as we were unable to have sufficient access to the financial information and management of the associate. Consequently, we were unable to determine whether any adjustments to these amounts and its comparatives were necessary.

The management of the Group is reviewing the above matters before taking all the appropriate actions to address these matters. To-date, the management has appointed an actuary firm to value the insurance liability.

A 3. Seasonal and Cyclical Factors

The Group's business operation results were not affected by any seasonal or cyclical factors.

A 4. Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no unusual items affecting the assets, liabilities, equity, net income or cash flow during the current financial quarter under review, that are unusual by reason of their nature, size or incidence.

A 5. Changes in Estimates

There were no changes in estimates of amounts reported in prior financial years, which have a material effect on the current financial quarter under review.

A 6. Debt and Equity Securities

There were no issuance, cancellation, repurchase, resale and repayment of debts and equity securities for the current financial quarter under review.

A 7. Dividends Paid

No dividends have been paid during this quarter.

A 8. Segmental Information

For management purposes, the Group is organised into two main business units based on its services, and has two reportable operating segments as follows :

- (i) Stem cell banking services – Provision of collection, testing, processing and preservation of umbilical cord blood stem cells (UCBSC), umbilical cord tissue (UCT) and peripheral blood stem cells (PBSC); and
- (ii) Corporate – investment in properties.

3 months ended 31.03.2015

	Stem cell banking services RM'000	Corporate RM'000	Eliminations RM'000	Consolidated RM'000
Revenue				
External	4,249	18	-	4,267
Inter-segment	42	15	(57)	-
Total revenue	4,291	33	(57)	4,267
Segment Results				
Profit/ (Loss) before taxation	353	(23)	-	330
Share of results of an associated company				(57)
Taxation				(63)
Profit after taxation				210

3 months ended 31.03.2014

	Stem cell banking services RM'000	Corporate RM'000	Eliminations RM'000	Consolidated RM'000
Revenue				
External	3,834	20	-	3,854
Inter-segment	174	15	(189)	-
Total revenue	4,008	35	(189)	3,854
Segment Results				
Profit/ (Loss) before taxation	248	(18)	-	230
Share of results of an associated company				13
Taxation				(63)
Profit after taxation				180

A 9. Valuation of Property, Plant and Equipment

There has been no valuation on any of the Group's property, plant and equipment during the current financial quarter under review.

A 10. Subsequent Events

There are no material events subsequent for the current reporting quarter.

A 11. Changes in the Composition of the Group

There are no changes in the composition of the Group during the current financial quarter under review.

A 12. Changes in Contingent Liabilities or Contingent Assets

There were no changes in the contingent liabilities or contingent assets since the last annual balance sheet date as at 31 December 2014.

A 13. Significant Related Party Transactions

	Current Year To Date 31.03.2015 RM'000
Significant transaction with a major shareholder of the Company :-	
(i) Testing fee	71
(ii) Royalties fee	133

**QUARTERLY REPORT
FOR THE FIRST QUARTER ENDED 31 MARCH 2015
(The figures have not been audited)**

NOTES TO THE INTERIM FINANCIAL STATEMENTS

PART B – EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF THE ACE MARKET

B 1. PERFORMANCE REVIEW

Quarter ended 31 March 2015

The Group recorded revenue of RM4.27 million against RM3.85 million (Q1 – 2014), an increase of 11%. This was mainly due to processing revenue arising from UCT - a new product and increase in storage income of 5% compared to the corresponding quarter. However, these were partly offset by a decrease in processing revenue from UCBSC of 22%.

Cost of sales decreased by 5% mainly due to lower number of new UCBSC signed-up case.

Gross profit was RM2.38 million (Q1 2014 – RM2.08 million) an increase of 14%. This was mainly due to contribution from UCT.

Administrative expenses increased by 1%. Selling & distribution expenses increased by 60% mainly due to higher advertising & promotion costs and staff costs.

Thai StemLife registered net loss and StemLife's share of the net loss was RM57,000 (Q1-2014 – profit RM13,000).

Net profit after taxation was RM210,000 compared to a profit of RM180,000 registered in the corresponding quarter, an increase of 17%. This was mainly due to revenue arising from UCT.

B 2. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	Q1 – 2015 RM'000	Q4 – 2014 RM'000
Revenue	4,267	5,077
Gross Profit	2,377	1,974
Profit / (Loss) Before Tax [PBT]	273	(1,674)
Profit / (Loss) After Tax [PAT]	210	(1,822)

For the quarter under review, the Group recorded revenue of RM4.27 million compared to RM5.08 million recorded in preceding quarter (Q4-2014), a decrease of 16%. This was mainly due to lower number of new UCBSC signed-up cases.

Gross profit was RM2.38 million compared to RM1.97 million in the preceding quarter, an increase of 20% from lower cost of sales.

The Group registered a profit after taxation of RM210,000 compared to loss of RM1.82 million in Q4-2014, mainly due to provision for insurance liability, write-off of prepaid service retainer bonus to a Director and allowance for doubtful debts in preceding quarter.

B 3. PROSPECTS OF THE GROUP

The Directors of StemLife are of the opinion that the Group's results for the financial year ending 31 December 2015 will continue to be challenging with no new development in the stem cell industry and government regulations.

B 4. VARIANCE OF ACTUAL AND FORECAST PROFIT

The Group did not issue any profit forecast for the financial period or year ending 31 December 2015 and therefore information on variance from profit forecast is not applicable.

B 5. TAXATION

The taxation figures are as follows:

	Current Quarter	Cumulative Year to Date
	RM'000	RM'000
Estimated current tax payable	63	63

The statutory corporate income tax rate applicable to StemLife is 25%. However, the company's income which is mainly derived from approved BioNexus activities i.e. involving its cord blood and peripheral blood stem cells banking activities, are not subjected to income tax. The income tax payable recorded for the period is a result of other income and profits of other subsidiaries which are subjected to Malaysian corporate income tax.

B 6. SALE OF UNQUOTED INVESTMENTS AND/OR PROPERTIES

There were no sales of any unquoted investments and/or properties for the current financial quarter and financial year to date.

B 7. PURCHASE OF QUOTED SECURITIES

There were no purchases of quoted securities during the financial period under review.

B 8. STATUS OF CORPORATE PROPOSALS

There is no corporate proposal announced but not completed as at the date of this report.

B 9. STATUS OF UTILISATION OF LISTING PROCEEDS

StemLife Berhad (“StemLife” or the “Company”) was listed on the ACE Market (formerly known as the MESDAQ Market) on 17 October 2006. The Company raised RM13.2 million from its Initial Public Offering (“IPO”) and the details of utilisation of such proceeds as at 31 March 2015 is as follows:

Purpose	Proposed Utilisation	Initial Timeframe for Utilisation	Actual Utilisation	Balance of Amount Allocated	%	Extended Timeframe for Utilisation	Explanations
	RM'000		RM'000	RM'000			
Third Laboratory	2,600	Within three (3) years from the Date of Listing i.e. 17 October 2006 (“Date of Listing”)	2,600	-	-	-	
Laboratory Equipments	3,000	Within three (3) years from Date of Listing	1,153	1,847	61.6	By 31 December 2015	^ ## ### #### #####
Logistics Expansion	600	Within three (3) years from Date of Listing	600	-	-	-	
Branches Expansion	2,500	Within three (3) years from Date of Listing	2,500	-	-	-	
Working Capital	2,500	-	2,998	(498)*	-	-	*
Listing Expenses	2,000	-	1,502	498*	-	-	*
	13,200	-	11,353	1,847	14	-	

Notes:

* The under utilisation of the listing expenses was adjusted to working capital and utilised fully in the 1st quarter 2007.

^ The approved timeframe for utilization is 3 years from the date of listing.

The Board of Directors had on 20 October 2009 approved and announced the extension of time for the utilisation of the balance of the IPO proceeds to 31 March 2012.

The Board of Directors had on 23 February 2012 approved and announced the extension of time for the utilisation of the balance of the IPO proceeds to 31 December 2013.

The Board of Directors had on 11 February 2014 approved and announced the extension of time for the utilization of the balance of the IPO proceeds in the extended timeframe mentioned.

The Board of Directors had on 10 February 2015 approved and announced the extension of time for the utilization of the balance of the IPO proceeds in the extended timeframe mentioned.

B 10. BORROWINGS AND DEBT SECURITIES

As at the current period under review, the Group does not have any borrowings and debt securities.

B 11. OFF BALANCE SHEET FINANCIAL INSTRUMENTS

As at the date of this report, there are no off balance sheet financial instruments.

B 12. MATERIAL LITIGATIONS

As at the date of this report, there are no material litigations against StemLife and its subsidiary companies or taken by StemLife and its subsidiary companies except for the following:

- (1) Suit against Bristol Myers Squibb Sdn Bhd (“BMS”) and Arachnid Sdn Bhd (“ASB”)
 - (i) The suit was filed by the Company in the Kuala Lumpur High Court on 22 May 2008 against BMS and ASB for defamatory articles posted on the MeadJohnson website. The Company sought relief by way of an injunction and damages.
 - (ii) BMS and ASB had on 26 September 2008 and 28 October 2008 respectively filed applications to strike out the Company’s claim on, inter alia, the basis that it disclosed no cause of action against them. The Company’s solicitors filed Affidavits in Reply to the said applications on 30 January 2009. BMS had also on 3 November 2008 amended its Statement of Defence and Counter Claim. As the amendment had no significant effect on the Company’s cause of action and its claim against BMS, the Company’s solicitors did not file any amendments to the Company’s Reply to Defence and Counterclaim.
 - (iii) At the scheduled hearing of the suit for case management of BMS and ASB’s applications to strike out the Company’s claim on 17 February 2009, the Court directed as follows:
 - (a) In respect of ASB’s striking out application, counsels for both ASB and the Company filed written submissions on 3 April 2009 and the hearing of the applications was fixed for 21 April 2009. The Company’s suit against ASB was struck off by the High Court on 21 April 2009. The Company appealed against the said decision on 30 April 2009.
 - (b) With regard to BMS’s striking out application, the hearing was fixed for 23 July 2009. At the hearing of BMS’s application the High Court struck out the Company’s suit against it. The Company has on 31 July 2009 filed an appeal against the said decision. The Court of Appeal had on 18 August 2010 heard both the appeals against ASB and BMS respectively and allowed both the Company’s appeals. The High Court had fixed 27 October 2010 for case management. Various case managements were held in relation to the preparation and filing of inter alia documents, statement of agreed facts and issues to be tried.
 - (iv) On 17 May 2012 the court directed that the matter be tentatively fixed for trial on 20, 21 and 22 November 2012. The parties informed the Court on 26 July 2012 that they have complied with the relevant case management directions to date. At the final case management on 9 November 2012 the parties informed the Court that they would proceed with the trial on the said dates.
 - (v) BMS withdrew its counter claim against the Company prior to the commencement of the trial on the scheduled dates. The trial was then proceeded with and it was completed at the continued hearing on 23 January 2013. The parties’ solicitors were directed to complete their

respective written submissions by 27 March 2013. The Court was to deliver its decision on 3 April 2013. It was deferred to 18 April 2013 for further clarifications and submissions.

- (vi) Subsequent to the clarifications and submissions from the parties' respective counsels on the said 18 April 2013, the Court reserved its decision to 17 May 2013.
- (vii) The Court vacated the date of 17 May 2013 that was scheduled for the delivery of its decision to 24 July 2013.
- (viii) The Court delivered its decision as follows:
 - (a) The Company's claim against BMS is allowed with costs and damages to be assessed in due course; and
 - (b) The Company's claim against ASB is dismissed with costs of RM30,000 to be paid by the Company to ASB.
- (ix) The Company has paid the costs awarded to ASB.
- (x) BMS filed an appeal to the Court of Appeal against the decision of the Court in allowing the Company's claim against them. The Court of Appeal has fixed 25 April 2014 for case management.
- (xi) In relation to assessment of damages against BMS, the Court directed the parties to file their respective written submissions simultaneously on or by 21 November 2013. As further time was required for the Company's Solicitors to file their written submissions the matter was fixed for another case management and on 24 January 2014, the parties informed the Court that they have filed their respective written submissions. The Court then directed the matter be fixed for further case management on 24 March 2014.
- (xii) The assessment of damages proceedings concluded on 24 March 2014 wherein the Court made the following orders:
 - (a) BMS was to pay RM200,000 to the Company as general damages for libel.
 - (b) BMS was to pay RM50,000 to the Company as aggravated damages.
 - (c) No award of exemplary damages for libel was made.
 - (d) General, aggravated and exemplary damages for loss of business and share value were not allowed.
 - (e) Interest at 5% was allowed on the judgment sum from the date of filing of the claim until full payment thereto.
 - (f) BMS was directed to pay the Company the costs of RM100,000.
- (xiii) The Company then instructed its solicitors to file an appeal against the decision of the Court in regard to the quantum of damages awarded. The notice of appeal was filed on 23 April 2014. BMS has also filed an appeal against the aforesaid decision.
- (xiv) On the said 25 April 2014, the Court of Appeal fixed the matter for further case management on 14 August 2014 so that all 3 appeals can be case managed together.
- (xv) The case was scheduled for further case management on 21 November 2014 pending the grounds of judgment on the assessment of damages. The Court has fixed 12 May 2015 for further case management.

B 13. DIVIDENDS

No dividends were declared during the financial quarter under review or the financial period year to date.

B 14. EARNINGS PER SHARE (“EPS”)

(i) Basic EPS

The basic EPS is calculated by dividing the net earnings attributable to shareholders for the period by the weighted average number of ordinary shares in issue during the period.

	First quarter ended	
	31.03.2015	31.03.2014
Net Profit Attributable to Ordinary Equity Holders of the Parent (RM'000)	210	180
Weighted Average Number of Ordinary Shares of RM0.10 each in Issue ('000s)	247,500	247,500
Basic Profit per Share (sen)	0.08	0.07

(ii) Diluted EPS

The company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial year to date.

B 15. DISCLOSURE OF REALISED AND UNREALISED RETAINED PROFITS

The breakdown of accumulative earning of the Group and the Company as at the reporting date, into realised and unrealised losses is as follows:

	As at 31.03.2015 RM'000	As at 31.12.2014 RM'000
- Realised	(9,257)	(9,525)
- Unrealised	(500)	(500)
	<u>(9,757)</u>	<u>(10,025)</u>
Total share of retained earnings from associated company		
- Realised	356	414
	<u>(9,401)</u>	<u>(9,611)</u>
Consolidation adjustments	5,875	5,875
Retained earnings per financial statements	<u>(3,526)</u>	<u>(3,736)</u>

B 16. DISCLOSURE ITEMS IN THE STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

	3 Months Ended		3 Months Ended	
	31.03.2015	31.03.2014	31.03.2015	31.03.2014
	RM'000	RM'000	RM'000	RM'000
Interest income	614	466	614	466
Investment income	-	-	-	-
Interest expense	-	-	-	-
Provision for and write off of receivables	-	-	-	-
Provision for and write off of inventories	-	-	-	-
Gain / (loss) on disposal of quoted or unquoted investments or properties	-	-	-	-
Impairment of assets / investments	-	-	-	-
Foreign exchange gain / (loss)	3	(4)	3	(4)
Gain / (loss) on derivatives	-	-	-	-
Exceptional items Gain / (loss) on disposal of fixed assets	1	-	1	-

B 17. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors of StemLife in accordance with a resolution of the directors dated 8 May 2015.

By Order of the Board

Laang Jhe How (MIA 25193)
Company Secretary
8 May 2015